Clinical Trials
830
131 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1947
Active, not recruiting
112
13.5%
Completed
465
56.0%
Enrolling By Invitation
2
0.2%
No Longer Available
1
0.1%
Not yet recruiting
17
2.0%
Recruiting
107
12.9%
Suspended
2
0.2%
Terminated
89
10.7%
Unknown
5
0.6%
Withdrawn
30
3.6%
No approval data available
- Inovio Pharmaceuticals is awaiting an Oct. 30 FDA target action date for INO-3107, an investigational DNA medicine for HPV 6- and HPV 11-associated recurrent respiratory papillomatosis. - In the Phase I/II RRP-001 study, 72% of patients had a 50% to 100% surgery reduction in year one, rising to 86% in year two. - The BLA was filed under accelerated approval, but the FDA's file acceptance letter preliminarily questioned eligibility because an RRP product already holds full approval. - Inovio has completed pre-licensure inspections and expects labeling discussions in September, while a confirmatory trial design still requires FDA agreement.
- The FDA approved daraxonrasib, sold as Rasonque by Revolution Medicines, for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy. - In the phase III RASolute 302 trial, median overall survival nearly doubled to 13.2 months with daraxonrasib versus 6.7 months with chemotherapy in 500 previously treated patients. - The oral once-daily multiselective RAS(ON) inhibitor targets KRAS mutations that drive tumor growth in more than 90% of pancreatic cancer cases, a target long considered undruggable. - Approval came 6.5 months ahead of the user fee deadline and carried Breakthrough Therapy, Orphan Drug and Priority Review designations, with common side effects including rash, diarrhea and stomatitis.
- A large international study of 14,246 patients found nearly 58% of younger adults with non-small cell lung cancer had guideline-recommended actionable mutations, versus about 45% of patients age 55 and older. - Younger patients were more likely to carry ALK, ROS1, and EGFR alterations, while older patients showed more KRAS-related changes and higher tumor mutational burden. - Researchers identified age-related differences in immune markers including LAG3 and TIGIT, suggesting potential targets for future immunotherapy strategies. - The findings support broader use of comprehensive genomic profiling, especially for younger adults who generally fall outside current lung cancer screening eligibility criteria.
- Cancer diagnosis rates in people under age 50 rose roughly 22% from 2000 to 2023, driving rapid growth in the oncofertility field. - Fertility preservation consultations for cancer patients surged, with Boston IVF's New England clinics rising from 19 patients in 2015 to 183 in 2025. - A Dana-Farber trial found early, hormone-sensitive breast cancer survivors could pause hormone therapy for up to two years to conceive without raising recurrence risk. - Despite progress, patients still face barriers including time pressure, limited awareness, and high out-of-pocket costs for fertility preservation.
- The NCI-led Human Cancer Model Initiative published 665 validated patient-derived organoid models covering 25 cancer types in Nature, doubling the number of in vitro models available globally. - The CSHL-Northwell Health consortium contributed over 150 organoid models, including rare and underrepresented cancer subtypes such as endometrial and pediatric cancers. - Each model is annotated with comprehensive clinical data, treatment history, and advanced molecular profiles including DNA/RNA sequencing and epigenetic data. - The resource has already expanded the Cancer Dependency Map, enabling CRISPR-based discovery of new therapeutic vulnerabilities across diverse cancer subtypes.
- NYU Langone Health and Dana-Farber Cancer Institute have co-developed Solavia Decision Suite, an oncology clinical decision support platform that launched internally on June 30 and is now commercially available. - The platform integrates directly into the electronic health record, providing oncologists with seamless access to the latest evidence, biomarkers, guidelines, and therapeutic options at the point of care. - The collaboration emerged after Philips sunset its oncology pathways business, prompting the two institutions to build a more robust, scalable, and workflow-integrated solution rather than adopt an existing vendor product. - Solavia is designed to strengthen care standardization, reduce unnecessary variation, and support precise, evidence-based treatment decisions across multidisciplinary cancer care teams.
- A 46-year-old triple-negative breast cancer patient became the first in the U.S. to undergo single-port robotic nipple-sparing mastectomy at a community hospital outside a clinical trial at Sutter's Alta Bates Summit Medical Center. - The FDA cleared the da Vinci single-port surgical system for nipple-sparing mastectomies in December 2025, based on a 53-patient randomized trial showing no difference in short-term safety compared to traditional procedures. - A 2024 JAMA Surgery case series of 20 women reported that 95% of breast-skin sensation and 55% of nipple sensation were preserved after the single-port robotic procedure. - The technique is limited to a select group of patients based on cancer type, location, breast size and shape, and is not suitable for most women with breast cancer.
- Germline genetic testing should be performed for all patients with metastatic or early-stage triple-negative breast cancer, according to Dana-Farber Cancer Institute oncologist Ilana Schlam, MD, MPH. - Tumor sequencing in the metastatic setting can identify targetable mutations that may open additional lines of therapy for patients. - Black patients tend to develop triple-negative breast cancer at earlier ages, and genetics has so far not been able to explain these racial disparities. - Ongoing research continues to investigate why differences in incidence and age of onset exist across race and ethnicity in triple-negative breast cancer.
- Cytosurge has elected veteran biotech executive and investor Luba Greenwood, J.D., to its Board of Directors, effective July 9, 2026, to support commercial growth and US expansion. - Greenwood, currently CEO of Mwyngil Therapeutics and former executive at Verily, Roche, and Dana-Farber's venture fund, brings decades of leadership across biotech, pharma, and AI. - Cytosurge's patented FluidFM® OMNIUM platform enables Same-Cell Biology by biopsying living cells without killing them, generating causal rather than correlational data for AI-driven drug discovery. - The company's technology is deployed in over 140 research labs worldwide, backed by more than 130 peer-reviewed publications and a Nature-validated methodology.
- Alison McCullough, a 39-year-old model, discovered a lump before New York Fashion Week but faced diagnostic delays due to age-based mammogram restrictions and limited access in Alaska. - She was diagnosed with triple-negative breast cancer with BRCA-2 mutation, an aggressive subtype accounting for 10–15% of all breast cancers with fewer targeted treatment options. - After facing further treatment delays in Alaska, McCullough relocated to City of Hope in Phoenix, where she received chemotherapy within days and later achieved cancer-free status following a double mastectomy. - Her story underscores persistent barriers to timely breast cancer diagnosis and care, particularly for younger women and those in rural or underserved regions.
